Zinostatin stimalamer

Drug Profile

Zinostatin stimalamer

Alternative Names: Neocarzinostatin, conjugate with styrene maleic acid anhydride copolymer; Poly(maleic acid-styrene)neocarzinostatin; SMANCS; YM 881; Zinostatin stimalamer

Latest Information Update: 11 Apr 2005

Price : $50

At a glance

  • Originator Kumamoto University
  • Developer Astellas Pharma; Kayaku; Kumamoto University; Kuraray
  • Class Cytostatic antibiotics; Enediynes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer
  • No development reported Brain cancer

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 26 Jul 2001 A clinical study in renal cell carcinoma has been added to the Cancer therapeutic trials section
  • 26 Sep 1997 A study in patients with liver cancer has been added to the therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top